Among cancers with substantially upregulated IGF2BP1 expression were four with reported pro-oncogenic roles of IGF2BP1 (LIHC, LUAD, OV and SKCM) as well as PAAD (Figure 1B). This evidence concerns the gene IGF2BP1 and cancer.